Medical Device Outsourcing Market: as Jabil pairs with a specialised electron beam sterilization provider to bring X-ray processing capacity online at a purpose-built greenfield site, the largest contract manufacturers are demonstrating that sterilization capacity, not just device assembly, has become a genuine capital investment decision in its own right, so device OEMs choosing an outsourcing partner increasingly need to evaluate a provider's sterilization modality breadth and capacity alongside its manufacturing scale, not treat sterilization as a downstream afterthought handled by a separate vendor.

The global medical device outsourcing market size was USD 165 Billion in 2025 and is expected to register a revenue CAGR of 10.1% during the forecast period. Market revenue growth is driven by factors such as regulatory compliance complexity pushing device OEMs toward specialised outsourcing partners, sterilization capacity investment expanding to meet growing device production volume, and contract manufacturing consolidation extending end-to-end service breadth across the device development lifecycle. The first driving factor is regulatory compliance complexity, as the FDA's transition from the Quality System Regulation to ISO 13485 alignment increases the specialised expertise required to maintain compliant quality and risk management systems. Contract manufacturing and materials account for approximately 55% of total 2024 market revenue, reflecting the centrality of end-to-end manufacturing outsourcing to overall device OEM cost and complexity management strategy. The second driving factor is sterilization capacity investment, as device manufacturers and their outsourcing partners expand modality-diverse sterilization infrastructure to meet growing device production volume. The third driving factor is contract manufacturing consolidation extending end-to-end service breadth, as the largest outsourcing providers acquire adjacent capabilities spanning testing, regulatory, and sterilization services. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single outsourcing provider's investment in a new sterilization modality converts a conventional contract manufacturing relationship into a broader end-to-end service offering that spans device assembly through terminal sterilization, which lets that provider capture a device OEM's sterilization spend within the same commercial relationship rather than requiring the OEM to coordinate a separate sterilization vendor. Because device OEMs increasingly prefer consolidating manufacturing and sterilization within a single outsourcing relationship to reduce supply chain coordination complexity and compress overall production timelines, a contract manufacturer that adds validated sterilization capacity, particularly for modalities like X-ray that offer genuine advantages over conventional ethylene oxide or gamma processing, directly expands its addressable share of an OEM's total outsourced spend. As a result, demand and revenue share are concentrating around outsourcing providers with the broadest validated sterilization modality portfolio alongside core manufacturing capability, and the forecast tilts toward end-to-end providers rather than manufacturers requiring OEMs to coordinate separate sterilization vendors. For instance, in February 2025, Jabil entered a collaboration agreement with Ebeam Applications S.A. to expand medical device sterilization outsourcing capability, deploying a Be-Wide X-ray sterilization solution at Jabil's new greenfield site in Byhalia, Mississippi, directly adding a validated sterilization modality to Jabil's existing contract manufacturing relationship with device OEM customers. These are some of the key factors driving revenue growth of the market.

Because outsourcing design and engineering work requires sharing proprietary device design details with an external partner, device OEMs with genuinely differentiated intellectual property often retain core design work in-house even while outsourcing manufacturing and testing, which caps how far outsourcing penetration can extend into the highest-value engineering activities regardless of cost advantages.

Quality system integration complexity between OEM and contract manufacturer processes is a second constraint, because a device OEM's quality management system must integrate reliably with its outsourcing partner's own quality processes to maintain regulatory compliance across the full manufacturing chain, and integration projects between two organisations' distinct quality systems frequently require more time and coordination than either party initially expects.

Sterilization capacity and modality availability constraints are a third constraint, since specialised sterilization modalities such as X-ray or electron beam processing require significant capital investment and validated facility capacity that remains concentrated among a limited number of providers, which can create bottlenecks during periods of high device production demand.

These factors substantially limit medical device outsourcing market growth over the forecast period.

The clearest driver of demand is regulatory compliance complexity, as the FDA's completed transition from the Quality System Regulation to ISO 13485 alignment increases the specialised expertise required to maintain compliant quality and risk management systems. A device OEM managing this compliance transition alongside core product development and commercialisation activities faces genuine capacity constraints, so specialised outsourcing partners with dedicated regulatory and quality expertise can absorb this complexity more efficiently than an OEM building equivalent capability entirely in-house. Contract manufacturing and materials account for approximately 55% of total 2024 market revenue, and the FDA completed its transition from the Quality System Regulation to ISO 13485 alignment in February 2024, directly increasing demand for regulatory compliance outsourcing services as device OEMs sought specialised partners to navigate the transition. The effect on the market is that regulatory compliance capability has become a genuine competitive differentiator for outsourcing providers, not simply an operational requirement to satisfy independently of the core manufacturing relationship. These are some of the key factors driving revenue growth of the market.

The second driver is sterilization capacity investment, as device manufacturers and their outsourcing partners expand modality-diverse sterilization infrastructure to meet growing global device production volume. Different sterilization modalities, including ethylene oxide, gamma, electron beam, and X-ray processing, each carry different material compatibility, throughput, and regulatory considerations, so a provider that can offer multiple validated modalities gives device OEMs meaningful flexibility to match sterilization method to specific device material and design requirements. In February 2025, Jabil entered a collaboration agreement with Ebeam Applications S.A. to deploy a Be-Wide X-ray sterilization solution at Jabil's new greenfield site in Byhalia, Mississippi, expanding the company's sterilization capability to serve medical device manufacturers with an additional validated modality option. The effect on the market is that sterilization modality breadth is becoming a genuine capacity investment decision for the largest contract manufacturers, not a service outsourced entirely to a separate specialist vendor. These are some of the key factors driving revenue growth of the market.

Jabil's Be-Wide X-ray sterilization deployment at its new Byhalia, Mississippi greenfield site adds a validated modality directly to its contract manufacturing relationship with device OEMs. Sterilization capacity is becoming a genuine capital investment decision for the largest contract manufacturers, not an afterthought handled by a separate vendor.

The third driver is contract manufacturing consolidation extending end-to-end service breadth, as the largest outsourcing providers acquire adjacent capabilities spanning testing, regulatory, and sterilization services to offer device OEMs a more comprehensive single-relationship outsourcing solution. A device OEM coordinating separate vendors for manufacturing, testing, and sterilization faces real supply chain coordination complexity and timeline risk at each vendor handoff, so a single provider offering end-to-end capability across these functions directly reduces this coordination burden and compresses overall production timelines. Eurofins Scientific announced its acquisition of Infinity Laboratories to expand its biopharma product testing offering in the United States, aligning with increasing demand for outsourced testing services covering sterility, biocompatibility, and quality assurance across the medical device outsourcing value chain. The effect on the market is that outsourcing providers with the broadest end-to-end service breadth are capturing a larger share of device OEM total outsourced spend per customer relationship. These are some of the key factors driving revenue growth of the market.

However, the medical device outsourcing market faces severe adoption constraints from intellectual property and design confidentiality concerns limiting how much design and engineering work OEMs will outsource, and quality system integration complexity between OEM and contract manufacturer processes.

Because outsourcing design and engineering work requires sharing proprietary device design details with an external partner, device OEMs with genuinely differentiated intellectual property often retain core design work in-house even while outsourcing manufacturing and testing, which caps how far outsourcing penetration can extend into the highest-value engineering activities regardless of cost advantages.

Quality system integration complexity between OEM and contract manufacturer processes compounds this, because a device OEM's quality management system must integrate reliably with its outsourcing partner's own quality processes to maintain regulatory compliance across the full manufacturing chain, particularly during the industry-wide ISO 13485 alignment transition, and integration projects between two organisations' distinct quality systems frequently require more time and coordination than either party initially expects.

Sterilization capacity and modality availability constraints are the third constraint, since specialised sterilization modalities such as Jabil's newly deployed X-ray processing require significant capital investment and validated facility capacity that remains concentrated among a limited number of providers, which can create bottlenecks during periods of high device production demand.

These factors substantially limit medical device outsourcing market growth over the forecast period.

Based on service type, the global medical device outsourcing market is segmented into contract manufacturing and materials, sterilization services, testing and quality assurance, regulatory affairs and clinical CRO services, packaging services, design and engineering services, supply chain and logistics, and software and digital health development. Contract manufacturing and materials holds the largest revenue share, accounting for approximately 55% of total 2024 market revenue, because end-to-end manufacturing outsourcing represents the most fundamental and highest-volume outsourcing relationship device OEMs establish, which suits a market where core production activity commands the largest revenue category. Sterilization services are expected to register the fastest revenue growth rate in the global medical device outsourcing market over the forecast period, driven by Jabil's expanded X-ray modality capacity and comparable investment extending sterilization capability directly into contract manufacturing relationships.

Based on device class, the global medical device outsourcing market is segmented into Class I, Class II, and Class III devices. Class II devices hold the dominant revenue share, accounting for approximately 81% of the market, because catheters, surgical instruments, and blood pressure monitors span the broadest range of moderate-risk device categories that outsourcing providers can serve without the highest-risk implantable device complexity of Class III devices. Class III devices are expected to register a significant revenue growth rate in the global medical device outsourcing market over the forecast period, driven by increasing outsourcing penetration into implantable and high-risk device categories as contract manufacturers demonstrate expanded quality system and regulatory capability.

Cardiology application is expected to account for the largest revenue share in the global medical device outsourcing market during the forecast period

Based on application, the global medical device outsourcing market is segmented into cardiology, diagnostic imaging, orthopedics, neurology, general surgery, ophthalmology, and diabetes care. Cardiology holds the largest revenue share, because cardiovascular device outsourcing spans the broadest range of catheter, stent, and interventional device manufacturing volume of any single therapy area. Diabetes care is expected to register the fastest revenue growth rate in the global medical device outsourcing market over the forecast period, driven by expanding continuous glucose monitoring and insulin delivery device production volume requiring specialised electronics and biocompatible materials manufacturing capability.

Based on regional analysis, the medical device outsourcing market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of contract manufacturing capacity and the FDA's QSR-to-ISO 13485 transition create the deepest outsourcing demand globally, and because Jabil, Flex, and Integer Holdings all maintain their primary commercial and manufacturing presence in the US market. Jabil's new Byhalia, Mississippi greenfield sterilization site specifically reinforces the depth of US domestic sterilization capacity investment. The US market reached approximately USD 30.96 billion in 2024, growing at a 13.0% CAGR, reflecting the scale of the domestic outsourcing relationship base.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent two of the largest national markets within the region, driven by expanding domestic contract manufacturing capacity and lower labour costs relative to developed markets. The region's rapidly scaling device manufacturing base leaves considerably more room for growth than in the already outsourcing-penetration-mature North American market.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, Ireland, and Switzerland represent significant national markets within Europe. The result is steady rather than rapid growth, shaped more by EU MDR compliance requirements affecting contract manufacturer quality systems than by underlying demand.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding contract manufacturing capacity driving early outsourcing demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the electronic components and specialised materials that Latin American contract manufacturers depend on, an effect expected to run through 2026 and slow medical device outsourcing capacity expansion beyond Brazil's and Mexico's main manufacturing centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding medical device manufacturing investment and the UAE's regional distribution hubs represent the primary investment centres for outsourcing adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the contract manufacturing infrastructure needed to support device outsourcing at scale.